AV-001 for COVID-19

Recruiting at6 trial locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Recruiting

Sponsor: Vasomune Therapeutics, Inc.

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial tests AV-001 Injection, a treatment to strengthen lung blood vessels and reduce inflammation, in hospitalized pneumonia patients needing extra oxygen. AV-001 works by mimicking a natural protein to make lung blood vessels stronger and less leaky.

Do I need to stop my current medications for this trial?

The trial protocol does not specify if you need to stop your current medications. However, if you have a serious medical condition or are taking certain medications that could interfere with the study, you may not be eligible to participate.

What data supports the idea that AV-001 for COVID-19 is an effective treatment?

The available research does not provide specific data on AV-001 for COVID-19. Instead, it discusses other treatments like APN01, which showed promising results in reducing symptoms in animal models and is moving towards human trials. Without specific data on AV-001, we cannot conclude its effectiveness for COVID-19 based on the provided information. ^{1 2 3 4 5}

What safety data is available for AV-001 treatment for COVID-19?

The provided research does not contain specific safety data for AV-001 treatment for COVID-19. The studies focus on allergic reactions to COVID-19 vaccines, adverse events in placebo arms of vaccine trials, tocilizumab treatment for COVID-19 pneumonia, polyethylene glycol allergies, and capillary leak syndrome following COVID-19 vaccination. None of these studies mention AV-001 or its analogs. ^{6 7 8 9 10}

Is the drug AV-001 Injection a promising treatment for COVID-19?

The information provided does not include any research or data about AV-001 Injection for COVID-19, so we cannot determine if it is a promising treatment. ^{11 12 13 14 15}

Research Team

Eligibility Criteria

This trial is for hospitalized patients with presumed pneumonia needing extra oxygen but not on mechanical ventilation or ECMO. They should have symptoms like new cough, fever, or breathlessness and signs of lung infection on imaging. Adults over 70 must be mentally stable and women able to bear children need effective contraception.

Inclusion Criteria

I have new or worsening symptoms like coughing, difficulty breathing, or changes in my sputum.

I am using effective birth control.

I have a high fever, fast breathing, unusual white blood cell count, or confusion if over 70.

Exclusion Criteria

I am on a ventilator or ECMO machine.

Pregnant and/or lactating women

Presence of any concurrent serious medical condition or concomitant medication that would preclude participation in the study including but not limited to: septic shock, multiple organ failure, moribund status, significant bleeding disorder or vasculitis, serious, nonhealing wound, peptic ulcer or bone fracture, liver cirrhosis, history of hypertensive crisis or hypertensive encephalopathy, severe renal insufficiency or end stage renal disease, ARDS risk factors, thromboembolic event within the past 3 months, symptomatic congestive heart failure, symptomatic or poorly controlled cardiac arrhythmia > class II, history of autonomic disorders or uncontrolled hypotension, hypersensitivity to drug products containing polyethylene glycol (PEG), any other condition which the Principal Investigator feels may jeopardize the safety of the patient or the objectives of the study

Treatment Details

Interventions

• AV-001 Injection (Other)
• AV-001 Placebo Injection (Other)

Trial Overview The study tests AV-001 Injection versus a placebo in addition to standard care for pneumonia. It's randomized and double-blind, meaning neither the doctors nor patients know who gets the real treatment. Patients receive daily doses until day 28 or hospital discharge.

Participant Groups

Group I: AV-001 Injection with standard of care (SOC). Active Control 1 Intervention

A total of 120 eligible patients (20 patients in each of cohort 1, 2 and 3 and 60 patients in cohort 4) will be randomized in a 1:1 ratio to receive either AV-001 Injection or AV-001 placebo Injection, together with standard of care (SOC). Doses of AV-001 Injection will start with 12.5 μg/kg/day in cohort 1 and are anticipated to increase to 25 μg/kg/day in cohort 2, 56 μg/kg/day in cohort 3 and to be determined (TBD) in cohort 4. The dose for cohort 4 will be determined by the Data Safety Monitoring Board (DSMB) based on emerging data from cohorts 1, 2 and 3.

Group II: AV-001 Placebo Injection with standard of care (SOC). Placebo Group 1 Intervention

A total of 120 eligible patients (20 patients in each of cohort 1, 2 and 3 and 60 patients in cohort 4) will be randomized in a 1:1 ratio to receive either AV-001 Injection or AV-001 placebo Injection, together with standard of care (SOC).

AV-001 Injection is already approved in Canada for the following indications:

Approved in Canada as AV-001 for:

• None approved; under investigation for Acute Respiratory Distress Syndrome (ARDS), pneumonia, and other conditions

Who Is Running the Clinical Trial?

Vasomune Therapeutics, Inc.

Lead Sponsor

Trials

2

Recruited

170+

Findings from Research

The CVnCoV vaccine candidate demonstrated low efficacy in a phase 3 trial, which was linked to the specific dose used and the presence of SARS-CoV-2 variants.

The vaccine's low efficacy was predicted by the neutralizing antibody response it generated, suggesting that both dosage and immune response play critical roles in its effectiveness.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Relating In Vitro Neutralization Level and Protection in the CVnCoV (CUREVAC) Trial. Cromer, D., Reynaldi, A., Steain, M., et al.[2023]

Aerosol administration of soluble human recombinant ACE2 (APN01) has shown the ability to neutralize SARS-CoV-2 in laboratory tests and has been well-tolerated in preliminary animal studies, indicating potential for use in humans.

Toxicology testing in dogs demonstrated no significant adverse effects from twice-daily aerosol administration over two weeks, paving the way for a Phase I clinical trial in healthy volunteers to further assess safety and efficacy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer. Shoemaker, RH., Panettieri, RA., Libutti, SK., et al.[2022]

Intranasal administration of soluble human recombinant ACE2 (APN01) in a mouse model significantly reduced weight loss and prevented death from SARS-CoV-2 infection, suggesting its potential efficacy in mitigating COVID-19 effects.

Aerosolized APN01 maintained its ability to bind the virus and perform its enzymatic function, with no notable toxicities observed in dogs during toxicity testing, paving the way for a Phase I clinical trial in humans.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Development of a novel, pan-variant aerosol intervention for COVID-19. Shoemaker, RH., Panettieri, RA., Libutti, SK., et al.[2022]

Researchers developed a new injectable formulation of Niclosamide nanoparticles (BSA-NIC-PEG NPs) that could effectively target the SARS-CoV-2 virus, showing promising stability and dispersibility in vitro.

While initial in vitro results are encouraging, further in vivo studies in virus-infected models are necessary to confirm the efficacy of this formulation, especially for elderly patients with hypoalbuminemia often seen in COVID-19 cases.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Injectable niclosamide nanohybrid as an anti-SARS-CoV-2 strategy. Rejinold, NS., Piao, H., Jin, GW., et al.[2022]

A new inhaled formulation of angiotensin receptor blockers (ARBs) has been developed to treat COVID-19, addressing safety concerns associated with oral administration and aiming for effective lung delivery.

In vitro studies show that this nanosuspension formulation is stable, retains drug activity, and effectively inhibits SARS-CoV-2 replication, with promising lung pharmacokinetics and tolerability observed in animal models.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Telmisartan Nanosuspension for Inhaled Therapy of COVID-19 Lung Disease and Other Respiratory Infections. Chen, D., Yun, X., Lee, D., et al.[2023]

In a study of 126 patients at risk for allergies to SARS-CoV-2 vaccines, 5% were found to have severe allergies to polyethylene glycol (PEG), which contraindicates the use of PEG-containing vaccines.

The skin testing protocol using PEG 1500 was effective in identifying PEG allergies, allowing 100 patients to safely receive vaccines containing PEG 2000 after confirming they did not have the allergy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Polythylene glycol severe allergy and SARS-CoV-2 vaccines: usefulness of testing with PEG 1500 extract. Gaspar, A., Moura, AL., Cruz, C., et al.[2023]

In a systematic review of 12 studies involving 45,380 participants, it was found that 35.2% of placebo recipients reported systemic adverse events (AEs) after the first dose of a COVID-19 vaccine, indicating a significant nocebo effect.

While vaccine recipients reported more AEs than those receiving placebo, a substantial portion of reported AEs in the placebo group (76.0% after the first dose and 51.8% after the second dose) were attributed to nocebo responses, highlighting the importance of addressing these concerns in vaccination programs.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Frequency of Adverse Events in the Placebo Arms of COVID-19 Vaccine Trials: A Systematic Review and Meta-analysis. Haas, JW., Bender, FL., Ballou, S., et al.[2022]

In a phase III trial (COVACTA) involving hospitalized patients with severe COVID-19 pneumonia, tocilizumab did not significantly reduce 28-day mortality compared to a placebo, indicating limited efficacy for this treatment in this patient population.

A real-world external comparator arm, matched to COVACTA participants, confirmed these findings, showing no significant difference in mortality rates between those treated with tocilizumab and those not exposed to the drug, suggesting that external comparators can effectively supplement RCT data.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Real-World Evidence to Supplement Randomized Clinical Trials: Tocilizumab for Severe COVID-19 Pneumonia vs. a Cohort Receiving Standard of Care. Skarbinski, J., Fischer, H., Hong, V., et al.[2023]

Capillary leak syndrome (CLS) was reported as a rare adverse event following COVID-19 vaccination, with 84 cases identified out of over 1.3 million reports, primarily associated with viral vector vaccines like ChAdOx1-SARS-COV-2 and Ad26.COV2-S.

The analysis indicated a significantly lower probability of CLS occurrence after mRNA vaccines (like BNT162b2 and mRNA-1273) compared to viral vector vaccines, suggesting a potential safety concern particularly with the Ad26.COV2-S vaccine.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Capillary leak syndrome following COVID-19 vaccination: Data from the European pharmacovigilance database Eudravigilance. Ruggiero, R., Balzano, N., Di Napoli, R., et al.[2022]

In a 48-week study involving 100 patients with macular edema due to retinal vein occlusion, treatment with ranibizumab led to a significant improvement in best-corrected visual acuity (BCVA) by an average of 7.7 letters, indicating its efficacy in a real-world setting.

The treatment also resulted in a significant reduction in central retinal thickness, from an average of 479.9 μm to 284.9 μm, demonstrating its effectiveness in reducing edema without any reported serious safety issues like endophthalmitis.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Sub-optimal gain in vision in retinal vein occlusion due to under-treatment in the real world: results from an open-label prospective study of Intravitreal Ranibizumab. Narayanan, R., Kelkar, A., Abbas, Z., et al.[2021]

In the BRAVO and CRUISE trials involving patients with macular edema from retinal vein occlusion, both doses of ranibizumab (0.3 mg and 0.5 mg) led to significant anatomical and visual improvements just 7 days after treatment.

After an initial 6-month treatment period, PRN (as needed) ranibizumab injections maintained visual improvements, although control group patients receiving PRN treatment showed less visual improvement compared to those in the treatment groups.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[BRAVO and CRUISE: ranibizumab for the treatment of macular edema secondary to retinal vein occlusion]. Figueroa, MS., Ruiz Moreno, JM.[2019]

In a study of 57 patients with macular edema due to branch retinal vein occlusion, all three treatments (aflibercept, ranibizumab, and dexamethasone implant) showed similar improvements in visual acuity and reduction in central macular thickness over six months.

While dexamethasone implant resulted in higher visual acuity at all time points, it also had more side effects, including increased intraocular pressure and cataract progression, compared to the anti-VEGF treatments.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A Real-Life Study: Intravitreal Aflibercept, Ranibizumab and Dexamethasone for Macular Edema Secondary to Branch Retinal Vein Occlusion. Bayat, AH., Bölükbasi, S., Erden, B., et al.[2022]

In a study of 377 patients treated with intravitreal aflibercept (IVT-AFL) for macular edema due to central retinal vein occlusion (CRVO), the treatment showed a favorable safety profile with only 5.84% experiencing adverse events over 24 months.

The treatment led to significant improvements in best corrected visual acuity (BCVA) and central retinal thickness (CRT), although the degree of improvement was less than that seen in randomized controlled trials, suggesting potential undertreatment in the clinical setting.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Real-World Data on Intravitreal Aflibercept for Macular Edema Secondary to Central Retinal Vein Occlusion: 24-Month Outcomes. Shimura, M., Fukumatsu, M., Tsujimura, J., et al.[2022]

The study found that withdrawing and storing the therapeutic antibody faricimab in specialized syringes for up to 37 days did not affect its structural integrity or bi-specific binding properties, ensuring its efficacy as a treatment.

Analyses showed no signs of degradation or aggregation of faricimab, indicating that it remains stable and effective for use in intravitreal injections during the storage period.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pharmaceutical compounding and storage of faricimab in a syringe for intravitreal injection do not impair stability and bi-specific binding properties. Jørstad, ØK., Foss, S., Gjølberg, TT., et al.[2023]

References

1. United States pubmed.ncbi.nlm.nih.gov

Relating In Vitro Neutralization Level and Protection in the CVnCoV (CUREVAC) Trial. [2023]

2. United States pubmed.ncbi.nlm.nih.gov

Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer. [2022]

3. United States pubmed.ncbi.nlm.nih.gov

Development of a novel, pan-variant aerosol intervention for COVID-19. [2022]

4. Netherlands pubmed.ncbi.nlm.nih.gov

Injectable niclosamide nanohybrid as an anti-SARS-CoV-2 strategy. [2022]

5. United States pubmed.ncbi.nlm.nih.gov

Telmisartan Nanosuspension for Inhaled Therapy of COVID-19 Lung Disease and Other Respiratory Infections. [2023]

6. United States pubmed.ncbi.nlm.nih.gov

Second-dose COVID-19 vaccines are well tolerated in patients with allergic reactions to the first dose - a single center experience. [2022]

7. Italy pubmed.ncbi.nlm.nih.gov

Polythylene glycol severe allergy and SARS-CoV-2 vaccines: usefulness of testing with PEG 1500 extract. [2023]

8. United States pubmed.ncbi.nlm.nih.gov

Frequency of Adverse Events in the Placebo Arms of COVID-19 Vaccine Trials: A Systematic Review and Meta-analysis. [2022]

9. United States pubmed.ncbi.nlm.nih.gov

Real-World Evidence to Supplement Randomized Clinical Trials: Tocilizumab for Severe COVID-19 Pneumonia vs. a Cohort Receiving Standard of Care. [2023]

10. Switzerland pubmed.ncbi.nlm.nih.gov

Capillary leak syndrome following COVID-19 vaccination: Data from the European pharmacovigilance database Eudravigilance. [2022]

11. England pubmed.ncbi.nlm.nih.gov

Sub-optimal gain in vision in retinal vein occlusion due to under-treatment in the real world: results from an open-label prospective study of Intravitreal Ranibizumab. [2021]

12. Spain pubmed.ncbi.nlm.nih.gov

[BRAVO and CRUISE: ranibizumab for the treatment of macular edema secondary to retinal vein occlusion]. [2019]

13. Turkey pubmed.ncbi.nlm.nih.gov

A Real-Life Study: Intravitreal Aflibercept, Ranibizumab and Dexamethasone for Macular Edema Secondary to Branch Retinal Vein Occlusion. [2022]

14. New Zealand pubmed.ncbi.nlm.nih.gov

Real-World Data on Intravitreal Aflibercept for Macular Edema Secondary to Central Retinal Vein Occlusion: 24-Month Outcomes. [2022]

15. England pubmed.ncbi.nlm.nih.gov

Pharmaceutical compounding and storage of faricimab in a syringe for intravitreal injection do not impair stability and bi-specific binding properties. [2023]